Intravacc develops innovative platforms and methods to improve the effectiveness, stability and safety of vaccines.
Intravacc is continuously investing in R&D platforms to facilitate vaccine development. Early development includes vaccine strain design to generate bacterial, viral and cellular seeds for efficient vaccine production.
We also carry out studies on adjuvants and delivery systems, resulting in safe products that are efficacious.
Our successful R&D efforts are then further developed into services we offer to clients.
To investigate the efficacy of vaccines, Intravacc performs immunological research to unravel the mechanisms of action of vaccine concepts. These immunological assays are used during preclinical and clinical stages.
Our expertise includes
Want to know more? Contact us at businessdevelopment@intravacc.nl
Intravacc develops bacterial and viral vaccines from discovery to phase II clinical trials. We use our own advanced technologies, such as Vero cell line and the OMV platform.
We can apply our long-standing and extensive experience in vaccine development to design rational and modelled processes together with our clients.
Using mathematical models we can safely scale from lab to commercial scale bioreactors.
Focusing on the treatment or prevention of viral diseases such as Polio, Respiratory Syncytial Virus, Enterovirus, Influenza, Rabies and Rotavirus. We have access to a qualified Vero cell line and specialized equipment to perform research for WHO, the Dutch Ministry of Health and collaborate with other parties.
Focusing on Conjugate vaccine technology (for vaccines for Hib and Shigella) and Outer Membrane Vescicles (OMV) technology (Pertussis, Meningococcal B, Lyme disease and Tuberculosis research)
Main features
Intravacc offers assay development and vaccine characterization services. We specialise in immunoassays, molecular biology methods, physicochemical analyses, and biological assays.
Assays to prove the quality of a new vaccine
The quality is a decisive factor in the development of new vaccines. Intravacc uses multiple instructive assays and innovative techniques to guarantee the quality of intermediates and finished product. Our tests focus on the composition, concentration, efficacy, purity, safety, stability and identity of the new vaccine candidate.
Immunoassays
Molecular biology methods
Physicochemical analyses
Analytical techniques
Biological assays
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Intravacc is one of the leading players in global 3R research (reduce, replace and refine animal experiments).
We have developed several new methods, some of which were accepted by the European Pharmacopoeia.
In addition, we are a front runner in the development and distribution of a new paradigm in vaccine lot release testing, known as the consistency approach. To promote the implementation of this strategy, we participate in an IMI-funded European consortium on consistency testing.
Research focus:
Achievements include:
Check out our factsheet on our 3R research
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Intravacc is home to a GMP facility for production of vaccines on pilot scale. This includes a state-of-the-art 100 m2 C/BSL-2 cleanroom.
Intravacc has years of experience in producing GMP batches for phase I and II clinical studies of viral and bacterial vaccines.
We have all the required equipment at our disposal for Upstream and Downstream Processing, including bioreactors of up to 100 liter.
This means we can offer a complete CTM production trajectory from seed lot production till released clinical batches.
Facilities
Want to know more? Contact us at: businessdevelopment@intravacc.nl
Our inhouse clinical and regulatory scientists form part of each project team that develops a new vaccine. They offer regulatory support right from the start.
Innovative vaccines are mostly complex products for which there is often no clear regulatory guidance available. That is why our Regulatory and Clinical Affairs (RCA) team is involved in the development of these products right from the start.
By taking into consideration the regulatory restraints and requirements in an early phase of development, a lean transition to the next phase towards a marketed product can be made.
Our team provides regulatory support in vaccine development projects through early involvement, assessment of potential regulatory requirements, preparation of risk assessments and by seeking informal or formal scientific advice with national competent authorities.
Support varies from the preparation of pharmaceutical, preclinical, and clinical development plans and reports, to the submission of relevant regulatory dossiers (IMPD/IND, CTA) to health authorities.
CMC activities
Nonclinical
Clinical
Want to know more? Contact us at: businessdevelopment@intravacc.nl
We are always open to work closely together with academia, public health organizations (WHO, BMGF), and biotech and pharmaceutical companies. This way, we benefit from each other's strengths in developing and innovating vaccines.
Are you looking for an experienced partner who can take your discovery to the next level of preclinical research?
Are you looking for a partner with GMP facilities, who can produce clinical lot material for your toxicity studies and phase I/II clinical trials?
Are you looking for a partner with a patent portfolio covering a variety of vaccine leads, novel vaccine technologies and adjuvants?
We are happy to discuss these and other possibilities for collaboration and co-development.
Vaccine concepts/technologies available for licensing
Want to know more? Contact us at businessdevelopment@intravacc.nl
Intravacc is an experienced R&D organization with a proven track record in vaccinology of over 100 years. We have a wide range of expertise to independently develop vaccines from lead concept to clinical phase I/II studies as wel as our own product pipeline and patents.
Check out our factsheet on Intravacc
Want to know more? Contact us at: businessdevelopment@intravacc.nl
News | 01-02-2019
Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.
News | 28-12-2018
Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.
News | 12-11-2018
Intravacc and BCHT have entered into a non-exclusive license agreement for the development of a Hib conjugate vaccine within the People’s Republic of China.
News | 15-10-2018
Intravacc has entered into a strategic partnership with TherapyX for the co-development of the world’s first prophylactic vaccine to provide lasting, protective immunity against Neisseria gonorrhoeae.
News | 04-06-2018
Serum Institute of India and Intravacc will jointly develop a novel delivery system for vaccines: Bioneedles - a tiny biodegradable mini implant with ground breaking potential.
News | 14-05-2018
The Dutch Ministry of Health, Welfare and Sport has announced the start of the privatization process of the activities of Intravacc. Collegium Advisors is to act as lead advisor and co-ordinator of the privatization process.
Intravacc today announced the establishment of Intravacc B.V. This is an important step in the anticipated privatization of Intravacc and the sale of its activities to a private party.
In May 2018, the Dutch Ministry of Health, Welfare and Sport announced the start of the privatization process of the activities of Intravacc a leading organisation in the field of vaccines research & development. As the privatization is progressing, the buyer of Intravacc is expected to be announced in the second quarter of 2019.
Preparing for the privatization, Intravacc B.V., a private company with limited liability, was established today. Once the shares of Intravacc are sold to the selected buyer, Intravacc B.V. will become operational and all assets, staff, intellectual property and contracts & agreements will be transferred to the new entity. This ensures a smooth transition of the business and the knowledge base of Intravacc with no interruption in servicing current customers.
Intravacc and CDBIO today announced that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.
Both parties will collaborate to tailor the Nonamen® concept for the Chinese market. Following the successful completion of this phase, CDBIO will receive a license to further develop and commercialize the vaccine.
Intravacc’s unique Nonamen® technology offers a broad panel of PorA proteins inserted in so called Outer membrane vesicles (OMV) expected to induce protection against the Meningococcal B (MenB) disease. Furthermore, the Nonamen® technology can be included in a Meningitis combination vaccine.
Under the agreement, both parties will collaborate to establish the development of an efficacious vaccine against prevalent Men B serotypes in China.
“We are very happy to partner with CDBIO and to be able to expand the global reach of our Nonamen technology. We trust this will help to prevent the occurrence of Men B in China considerably”, said Mr Nico Oudendijk, General Director of Intravacc.
Intravacc and BCHT have entered into a non-exclusive license agreement for the development of a Hib conjugate vaccine within the People’s Republic of China.
Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China. By combining their strengths, the two parties can together lower the incidence of this vaccine preventable disease in China.
Through this agreement, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children.The license agreement between Intravacc and BCHT will now help to reduce the incidence of Hib in Chinese children.
Of the 6 types of H influenzae, type B is responsible for more than 90% of systemic infections. Hib can cause serious illness like acute lower respiratory tract infection and bacterial meningitis. In China, for children under age of 5 years old, the incidence of meningitis caused by Hib was reported in a survey about 10.7/100 000 annually; 9.7% of these cases were fatal, and 21.4% of survivors suffered from neurological or psychological problems. The agreement between Intravacc and BCHT will help to bring this number down considerably.
‘’It’s great to hear that the innovative work of our researchers at Intravacc will contribute to the prevention of Hib in China. We are proud to partner with BCHT to prevent this disease.” said Mr Nico Oudendijk, General Director of Intravacc.
Intravacc has entered into a strategic partnership with TherapyX for the co-development of the world’s first prophylactic vaccine to provide lasting, protective immunity against Neisseria gonorrhoeae.
Intravacc is pleased to announce that it has entered into a strategic partnership with TherapyX for the co-development of NGoXIMTM, the world’s first prophylactic vaccine against infection with Neisseria gonorrhoeae. This new vaccine is intended to enhance specific adaptive immune responses that provide lasting, protective immunity against N. gonorrhoeae. NGoXIMTM is a combination of a sustained-release formulation of interleukin 12 (GneX12TM) and bacterial outer membrane vesicles (OMV) formulated for mucosal delivery.
No effective gonorrhea vaccine is currently available and the disease is known to be acquired repeatedly with apparently no development of protective immunity from previous infection. The American Centers for Disease Control and Prevention (CDC) has listed antibiotic-resistant N. gonorrhoeae as one of the top three pathogens presenting “an immediate public health threat that requires urgent and aggressive action.” A recent WHO technical consultation on vaccines against sexually transmitted infections (2017) called for renewed efforts to develop a vaccine against gonorrhea. This partnership effort is a direct response to that call.
Under the terms of the partnership agreement, TherapyX will focus efforts on IND-enabling efficacy and toxicology studies in primates while Intravacc will be responsible for the discovery and development of OMVs with improved immunogenic properties and reduced toxicity. Financial terms were not disclosed.
“We are thrilled to partner with Intravacc” said Dr. Dominick L. Auci, Vice President for Research and Development at TherapyX. “They bring over 100 years of expertise in vaccines including novel OMV technology to this important project. We couldn’t be working with a more experienced, innovative and dedicated team”.
“We are delighted to be working with TherapyX” said Mr. Nico Oudendijk, General Director of Intravacc. “The IL-12 technology they bring into the project is key to develop an efficacious vaccine against this disease.”
New Delhi/Bilthoven, 29th May 2018: Life Sciences and Healthcare is a vital area of collaboration for India and the Netherlands. Growing market opportunities in India, combined with the Netherlands’ strengths in Healthcare, create excellent opportunities for Indo-Dutch partnerships that address shared societal challenges with smart solutions. One of the key healthcare challenges that are being turned into Indo-Dutch collaborative solutions is vaccine delivery.
Serum Institute of India and Intravacc (part of the Netherlands Ministry of Health, Welfare and Sports) will jointly develop a novel delivery system for vaccines: Bioneedles. The Bioneedle, a tiny biodegradable mini implant, is a unique approach with ground breaking potential to transform vaccination campaigns, especially in low and middle income countries. The parties will develop Bioneedles for vaccines against measles and rubella. The Memorandum of Understanding confirming their collaboration was signed in the presence of Mark Rutte, Prime Minister of the Netherlands, Sigrid Kaag, Dutch Minister for Foreign Trade and Development Cooperation, Bruno Bruins, Dutch Minister for Medical Care and Sports, Hans de Boer, CEO, Confederation of Netherlands Industry and Employers VNO-NCW, and H.E Alphonsus Stoelinga, Ambassador of the Netherlands to India, during the Netherlands Trade Mission to India last week. The signatories were Dr Suresh Jadhav, Executive Director, Serum Institute of India and Thijs Veerman, CEO, Intravacc.
“I am happy that this MoU was signed during The Netherlands Trade mission to India. The collaboration between SII and Intravacc is a good example of a cooperation in which companies from India and The Netherlands join forces to help improve health worldwide,” Bruno Bruins, Minister for Medical Care of The Netherlands was quoted as saying.
Currently, vaccines are mostly administered through intramuscular or subcutaneous injection by needle and syringe. The use of needles however may cause pain and fear in vaccinated people, and requires trained personnel, which is not always readily available in low and middle income countries. Moreover, needle waste can be hazardous due to reuse and needle-stick injuries and, as a result, transmission of infectious diseases like hepatitis or HIV. To overcome these issues, numerous alternative vaccine administration devices and methods are currently being developed.
One of the most promising technologies in alternative vaccine delivery is a Bioneedle-based delivery device. “Vaccines play a critical role in public health globally- and for Intravacc, India is a vital market for partnerships in vaccine development. This project could potentially mark a major step towards vastly improved access to vaccines especially in low and middle income countries. We are very happy to be involved in such an innovative project with our Indian partner,” Thijs Veerman, CEO, Intravacc says.
Bioneedles are composed of a starch-like polymer, a product that is naturally degraded by the human body. The Bioneedle is administered by an implantation under the skin with an applicator. The Bioneedle matrix will degrade after implantation, which enables the release of the freeze dried vaccine. This reduces hazardous needle waste and results in a quick and pain-free delivery of the vaccine; it may even abolish the need for trained professionals to perform vaccinations – a huge benefit in developing countries where trained medical personnel is scarce. In addition, vaccines in Bioneedles are both freeze and heat stable and can be stored, transported and distributed outside any cold chain. Preclinical concepts of Bioneedles have been established with numerous vaccines, including tetanus, polio, influenza and hepatitis B. In all cases, Bioneedles filled with vaccine were able to induce potent systemic humoral immune responses against the respective antigen. Serum Institute of India and Intravacc will jointly develop Bioneedles for vaccines against Measles and Rubella. Intravacc will optimize the formulation of the vaccine and preparation of the Bioneedles and freeze drying process; Serum Institute of India will supply the MR vaccine. Both parties will search for a partner, preferably from India, for developing a suitable applicator device to administer the Bioneedles.
“We are now the world's largest vaccine manufacturer by number of doses produced. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute, saving millions of lives throughout the world,” says Dr Suresh Jadhav, Executive Director, Serum Institute of India. With this project we continue to build a sustainable, long-term partnership with Intravacc in our effort to manufacture affordable life-saving vaccines .”
All together this is a unique approach with ground breaking potential to transform vaccination campaigns, especially in the low and middle income countries.
The Dutch Ministry of Health, Welfare and Sport has announced the start of the privatization process of the activities of Intravacc. Collegium Advisors is to act as lead advisor and co-ordinator of the privatization process.
Bilthoven, May 8th, 2018 - The Dutch Ministry of Health, Welfare and Sport (Ministerie van Volkgezondheid, Welzijn en Sport or MoH) has announced the start of the privatization process of the activities of Intravacc.
Intravacc (Institute for Translational Vaccinology) has a wide range of relevant expertise in independently developing vaccines from lead concept to clinical phase I/II studies, and has its own product pipeline and patents. Moreover, it provides and contracts R&D services to a range of public and private customers. During the last several decades, Intravacc has positioned itself as a global leader in the development of vaccines aiding in the eradication of Polio and has engaged in the research and development of bacterial and viral vaccines against, amongst others, Respiratory Syncytial Virus (RSV), Shigella, Rotavirus, Hib and DTP.
Intravacc was originally formed to perform public tasks concerning research and development of new vaccines resulting from the ambitions and objectives set out by the Dutch State. The company’s aim is to develop safe, effective and affordable vaccine concepts in order to find sustainable solutions to improve public health worldwide. Intravacc is located in Bilthoven, the Netherlands, where it operates state-of-the-art R&D and Good Manufacturing Practice (GMP) facilities for conducting vaccine research.
As a result of the increasing commercial focus of the organization and its close collaboration with the (global) pharmaceutical industry and Global Health parties such as the World Health Organization and the Bill and Melinda Gates Foundation, MoH decided Intravacc would be better suited in a private setting. In June 2015, the Minster of MoH informed the Dutch House of Representatives on its intent to privatize Intravacc and, has now obtained all required political approval to commence the privatization process in order to secure a suitable prospective buyer.
Collegium Corporate Finance and Valuation Advisors has been appointed to act as lead advisor to the MoH during the privatization of Intravacc. Collegium will aim to inform potential prospective buyers about the timelines and structure of the privatization process. Any contact and all expressions of interest with regards to the privatization process should be expressed via Collegium (Intravacc@CollegiumAdvisors.com).
Contact details: Collegium Corporate Finance and Valuation Advisors,
Joachim Schulz, Managing Director, Tel: +31-10 203 7856.
Correspondence address: Westplein 11, 3016 BM Rotterdam, The Netherlands.
At Intravacc we often have possibilities for internships for relevant MBO-, HBO-, and WO students.
The practical work of vaccine development is divided in 4 departments. Are you looking for an interesting and challenging internship? Then check below to see what each department has to offer.
If you are interested please send an email to Human Resources: personeelszaken@intravacc.nl
Make sure your email includes the following information:
We will let you know if we have availability during the time requested.
Please note that you need to be vaccinated to access the laboratories. The necessary vaccinations will be provided by Intravacc free of charge.
In this department we develop processes for the production of bacterial vaccines. Most bacterial vaccines developed by Intravacc are either outer membrane vesicles vaccines or conjugate vaccines against many different pathogenic microorganisms. During process development we focus on the cultivation of bacteria (upstream processing, USP) and the purification of the vaccine from the culture broth (downstream processing, DSP). Processes are developed and each unit operation is optimized.
To answer the research questions and to meet the deliverables you will, during your internship, work with shaker flasks and bioreactors (from 1L to 70L and multi reactor systems) for the USP. For the DSP you will work with centrifugation and filtration techniques, these include dead-end and tangential flow filtration as well as size exclusion chromatography.
For conjugation technologies you will purify polysaccharides and perform chemical reactions to conjugate these polysaccharides to carrier proteins. This work involves analytical equipment like HPLCs. The department has a state of the art laboratory well equipped for all the research performed.
We often have openings for internships in all expertises described above.
===========================================================
In this department, we design, generate and test concept vaccines. Expertise represented in the department include molecular biology, virology, bacteriology, immunology and regulatory and clinical affairs.
For vaccine design we investigate which antigens are suitable to include in a vaccine:
This information is combined to design new bacterial, viral or cellular strains using molecular biological techniques. Next, these strains are tested in production processes by the process development departments and within ECR we study the efficacy and safety of these vaccines both in vitro and in vivo, using an array of immunological techniques. Of note, we strive to design new in vitro techniques that can replace animal experiments as much as possible.
Throughout the whole vaccine chain it is important to monitor the feasibility of a concept vaccine from a technical and economical, but also from a regulatory and clinical point of view. Since the product is meant to be used in healthy people, there are many criteria to be met and it is crucial to substantiate which choices have been made and why.
At ECR we often have openings for internships related to strain design and immunology.
This department designs, develops and improves processes for production of viral vaccines. Disciplines in the department are:
This means that a broad range of internships are possible in the PDVV department. Ranging from working with cell culture using bioreactors, focusing on purification technologies using Äkta systems and in depth mathematical calculations using specialized software, but also establishing routines for various analysis methods like virus titration and ELISA. The department uses state-of the art equipment in recently renovated laboratories at BSL2/ML-II/MI-III level.
==============================================================
This department focuses on the development of analytical tests, stable formulation and appropriate methods for administration of (new) vaccines. To facilitate efforts throughout Intravacc, ADF is structured in the following expertise groups:
We often have interesting internship assignments for students.
Intravacc is een toegepast wetenschappelijk onderzoekinstituut dat onderzoek doet naar nieuwe vaccins. Door Intravacc worden enerzijds veelbelovende ideeën uit de wetenschap beschermd en verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Anderzijds wordt door Intravacc de beschikbare kennis op het gebied van vaccinontwikkeling en -productie ingezet om R&D opdrachten voor klanten uit te voeren.
Het instituut rekent zowel de (inter)nationale overheid als bedrijven, onder andere binnen de innovatieve farmaceutische industrie, tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd, dus volop in beweging
De afdeling ECR ontwikkelt, analyseert en toetst vaccine oncepten door middel van pre-klinisch onderzoek. Hierbij ligt de nadruk op moleculaire biologie en immunologie. Binnen de afdeling ECR zijn wij op zoek naar een full time onderzoeksmedewerker immunologie.
Als onderzoeksmedewerker ben je verantwoordelijk voor het uitvoeren van experimentele werkzaamheden die betrekking hebben op het testen van de veiligheid en werkzaamheid van vaccins. Er wordt verwacht dat je je werkzaamheden voorbereidt in overleg met ervaren collega’s en dat je de experimenten zelfstandig uitvoert en nauwgezet documenteert, in zowel labjournaals als rapportages.
Vaccinontwikkeling, immunologie, celkweek, ELISA, flow cytometrie, Elispot
Het salaris is, afhankelijk van opleiding en relevante werkervaring, maximaal € 3.521,52 bruto per maand (BBRA-schaal 8) op basis van een volledig dienstverband (36-urige werkweek), exclusief 16,37% Individueel Keuze Budget.
De aanstelling zal plaatsvinden op basis van indeling Functiegebouw Rijk, Onderzoeksmedewerker. Het betreft een functie in tijdelijke dienst voor de duur van 1 jaar met uitzicht op vast dienstverband.
Informatie
Voor meer informatie kun je contact opnemen met mevr. dr. E. van Riet (T: 0307920504).
Wij ontvangen je sollicitatie (o.v.v. vacaturenummer INT123) graag uiterlijk 30 januari 2020 digitaal via personeelszaken@intravacc.nl
Let op VWNW en interne kandidaten genieten de voorkeur.
Download de vacaturetekst (pdf)
Acquitisite naar aanleiding van deze vacature wordt niet op prijs gesteld.
Het Instituut voor Translationele Vaccinologie (Intravacc) is dé plek in Nederland met een breed toegankelijke en complete infrastructuur voor translationele vaccinonderzoek en -ontwikkeling. Op het instituut worden goede ideeën uit de wetenschap verder geholpen op het pad naar vaccins die waardevol zijn voor zowel de volksgezondheid als het bedrijfsleven. Het instituut rekent zowel de (inter)nationale overheid als diverse big pharma bedrijven tot haar klanten. In het komend jaar zal het instituut worden verzelfstandigd tot een publiek-private onderneming.
Binnen de afdeling Finance hebben wij een uitdagende functie voor een:
In de functie van Junior Controller ben je onderdeel van de Finance & Accounting groep van Intravacc, die zorg draagt voor de juiste en tijdige administratie en hierover rapporteert aan belanghebbenden binnen en buiten de organisatie. Je rapporteert aan de CFO.
In deze functie ben je verantwoordelijk voor de volgende taken:
Algemeen
Projectmanagement
Je bent een financiële medewerker met enkele jaren bedrijfservaring, opgedaan als assistent controller of junior (project) controller. Je beschikt over een financiële opleiding accountancy, bedrijfsadministratie of bedrijfseconomie op minimaal HBO niveau. Daarnaast beschik je over een uitstekend analytisch vermogen en je maakt financiële pakketten snel eigen. Excel kent weinig tot geen geheimen voor je, je bent accuraat en ziet verbanden tussen de cijfers. Je bent communicatief vaardig, zowel mondeling als schriftelijk. Je bent goed in staat financiële data om te vormen tot informatie voor belanghebbenden.
Het salaris is, afhankelijk van opleiding en ervaring, maximaal EUR € 3.521,52 bruto per maand (BBRA-schaal 8 per 1 januari 2020). Het salaris is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering.
De aanstelling zal plaatsvinden op basis van de indeling Functiegebouw Rijk, Adviseur bedrijfsvoering (schaal 8).
Voor meer informatie over de functie kun je terecht bij de CFO van Intravacc, Rob van Zeeland, tel. 030- 7920 561.
Wij ontvangen je sollicitatie graag uiterlijk 23 januari 2020 digitaal via personeelszaken@intravacc.nl
Let op de VWNW en interne kandidaten genieten de voorkeur.
Download de vacaturetekst (pdf)
Acquisitie n.a.v. deze vacature wordt niet op prijs gesteld.
Intravacc is een toegepast wetenschappelijk onderzoekinstituut dat humane vaccins ontwikkelt. Enerzijds worden veelbelovende ideeën uit de wetenschap verder ontwikkeld tot waardevolle vaccins. Anderzijds wordt door Intravacc de beschikbare kennis op het gebied van vaccinontwikkeling en -productie ingezet om R&D opdrachten voor klanten uit te voeren.
Het instituut rekent zowel de (inter)nationale overheid als bedrijven tot haar klanten. Komend jaar zal het instituut worden geprivatiseerd.
Wij zijn op zoek naar een ervaren projectleider die verantwoordelijk is voor het managen van (grote) vaccin ontwikkelprojecten. De projecten kunnen de gehele ontwikkelketen omvatten of een deel daarvan: van proof-of-concept tot en met vroege klinische ontwikkeling. Je draagt zorg voor de planning, uitvoering en rapportage. Projectteams bestaan uit medewerkers van verschillende afdelingen. Je rapporteert aan de programmamanager(s) van programma’s waarin je projecten zijn ondergebracht. Je hiërarchisch leidinggevende is de CSO. Daarnaast onderhoud je contacten met afdelingshoofden die mensen en apparatuur beschikbaar stellen en over inhoudelijke deskundigheid beschikken. Grote projecten doorlopen verschillende stadia waarbij stage gating technieken worden toegepast. Opdrachtgevers zijn NGOs, vaccinproducenten, biotechnologiebedrijven en de eigenaar van Intravacc. Daarnaast wordt samengewerkt met academische centra en/of hun spin-out bedrijven.
Je bent verantwoordelijk voor:
Het salaris is, afhankelijk van opleiding en relevante werkervaring, maximaal € 5671,10 bruto per maand (maximaal BBRA-schaal 12 per 1-1-2020). Het salaris is gebaseerd op een volledig dienstverband (36-urige werkweek), exclusief 8% vakantietoelage en 8,3% eindejaarsuitkering.
De aanstelling zal plaatsvinden op basis van de indeling Functiegebouw Rijk, Project-/Programmamanagement.
Voor meer informatie over de functie kun je terecht bij de heer E. de Ridder, tel. 030 – 7920 521, e-mail erik.de.ridder@intravacc.nl.
Wij ontvangen je sollicitatie graag uiterlijk 19 december 2019 digitaal via personeelszaken@intravacc.nl
Let op de VWNW en interne kandidaten genieten de voorkeur.
Download de vacaturetekst (pdf)
Acquisitie naar aanleiding van deze vacature wordt niet op prijs gesteld.
